Pharmaceutical Dihexa Powder Peptide Dihexa 1401708-83-5

Physical Characters and specifications

Dihexa, also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is a synthetic peptide derivative designed to mimic the neuroprotective and cognitive-enhancing effects of ctor ( ). Structurally, it consists of a modified hexapeptide sequence with a C-terminal 6-aminohexanoic acid tail, enhancing its metabolic stability and blood-brain barrier penetration. Dihexa exhibits a molecular weight of 760.94 g/mol and appears as a white to off-white lyophilized powder, soluble in dimethyl sulfoxide (DMSO) and sparingly soluble in aqueous buffers. Its stability is optimal when stored at -20°C under inert conditions, protected from light and moisture. Analytical characterization by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) confirms a purity of ≥98%, with minimal impurities such as des-Tyr or deamidated byproducts. The compound's mechanism hinges on its high-affinity binding to the c-Met receptor, activating downstream pathways like PI3K/Akt and MAPK/ERK, which promote neuronal survival, synaptic plasticity, and angiogenesis. Dihexa's unique pharmacokinetics—oral bioavailability and prolonged half-life—distinguish it from natural , making it a promising candidate for neurotherapeutic applications.

Dihexa is a small peptide composed of eight amino acids, and it is closely associated with cognitive enhancement and potential neurological benefits. It is a derivative of the angiotensin IV, which has been studied for its effects on memory and learning. Researchers have investigated Dihexa for its ability to promote synaptogenesis, the formation of new synapses in the brain, which may help in conditions such as neurodegenerative disorders and cognitive decline.

Dihexa has emerged as a potent nootropic and neurorestorative agent, primarily due to its ability to enhance cognitive function and repair neural damage. Preclinical studies highlight its efficacy in improving memory consolidation, learning, and executive function in rodent models of Alzheimer's disease (AD) and traumatic brain injury (TBI). By stimulating neurogenesis and synaptogenesis, Dihexa reverses amyloid-beta-induced toxicity and restores dendritic spine density in hippocampal neurons. Beyond neurodegenerative diseases, it shows potential in stroke recovery by reducing infarct volume and improving motor coordination. Its angiogenic properties further support applications in vascular dementia and diabetic neuropathy. In psychiatry, Dihexa's modulation of brain-derived neurotrophic (BDNF) suggests utility in depression and PTSD, where synaptic atrophy is a hallmark. Unlike conventional therapies requiring invasive delivery, Dihexa's oral activity and blood-brain barrier permeability offer a practical route for chronic administration. Current research explores its use in combination therapies, such as pairing with acetylcholinesterase inhibitors for synergistic AD treatment. Despite its promise, further clinical trials are needed to validate safety and efficacy in humans, particularly regarding long-term effects on oncogenic pathways linked to c-Met activation. Pending regulatory approvals, Dihexa could revolutionize neuropharmacology by addressing unmet needs in cognitive decline and CNS injuries.

We are manufacture of  Semaglutide , Tirzepatide, Retatrutide raw power and lyophilised powder with different specification, such as 5mg,10mg,15mg, 20mg, 30mg, 60mg or  customized.